Compare Stocks → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALRNNASDAQ:CLSNNASDAQ:GANXNASDAQ:RZLTNASDAQ:VBLT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRNAileron Therapeutics$5.06+2.6%$5.41$1.01▼$7.42$85.87M2.2264,769 shs80,550 shsCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsGANXGain Therapeutics$3.07-3.8%$4.04$2.00▼$5.65$49.80M0.43154,054 shs142,396 shsRZLTRezolute$2.60-10.0%$2.17$0.72▼$3.69$104.33M1.29314,242 shs454,240 shsVBLTVascular Biogenics$5.46-8.8%$0.40$0.10▼$6.74$423.91M0.772.19 million shs161,505 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRNAileron Therapeutics+3.79%+16.00%-14.56%+1.86%+230.89%CLSNImunon0.00%0.00%0.00%0.00%0.00%GANXGain Therapeutics-5.90%+0.31%-12.60%-10.01%-35.43%RZLTRezolute+1.05%-10.80%+52.91%+158.04%+40.98%VBLTVascular Biogenics0.00%0.00%0.00%0.00%+3,207.09%The Gold Grab of the Century (Ad)When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRNAileron Therapeutics1.319 of 5 stars3.53.00.00.00.61.70.0CLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AGANXGain Therapeutics3.1038 of 5 stars3.53.00.00.03.82.50.6RZLTRezolute3.7367 of 5 stars3.54.00.00.03.74.20.6VBLTVascular BiogenicsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRNAileron Therapeutics3.00Buy$19.00275.49% UpsideCLSNImunonN/AN/AN/AN/AGANXGain Therapeutics3.00Buy$8.50176.87% UpsideRZLTRezolute3.00Buy$8.80238.46% UpsideVBLTVascular BiogenicsN/AN/AN/AN/ACurrent Analyst RatingsLatest ALRN, GANX, VBLT, RZLT, and CLSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2024GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/23/2024GANXGain TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.004/18/2024ALRNAileron TherapeuticsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $19.004/18/2024RZLTRezoluteJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$7.004/18/2024RZLTRezoluteJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/9/2024RZLTRezoluteMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.004/1/2024GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/27/2024GANXGain TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/7/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.002/14/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/ACLSNImunon$500K0.00N/AN/A$9.66 per share0.00GANXGain Therapeutics$50K995.91N/AN/A$0.97 per share3.16RZLTRezoluteN/AN/AN/AN/A$3.15 per shareN/AVBLTVascular Biogenics$660K642.29N/AN/A$0.32 per share17.06Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRNAileron Therapeutics-$15.73M-$3.38N/AN/AN/AN/A-130.32%-39.23%5/13/2024 (Estimated)CLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AGANXGain Therapeutics-$22.27M-$1.71N/AN/AN/AN/A-193.03%-123.21%5/10/2024 (Estimated)RZLTRezolute-$51.79M-$1.10N/AN/AN/AN/A-51.81%-48.05%5/9/2024 (Estimated)VBLTVascular Biogenics-$32.30M-$0.21N/A∞N/AN/A-73.45%-54.11%N/ALatest ALRN, GANX, VBLT, RZLT, and CLSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/15/2024Q4 2023ALRNAileron TherapeuticsN/A-$1.54-$1.54-$1.54N/AN/A3/26/2024Q4 2023GANXGain Therapeutics-$0.32-$0.29+$0.03-$0.29N/AN/A2/13/2024Q2 2024RZLTRezolute-$0.27-$0.27N/A-$0.27N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRNAileron TherapeuticsN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/AVBLTVascular BiogenicsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRNAileron TherapeuticsN/A4.174.17CLSNImunon0.136.526.52GANXGain Therapeutics0.043.593.59RZLTRezoluteN/A12.0012.00VBLTVascular BiogenicsN/A4.634.63OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRNAileron Therapeutics90.89%CLSNImunon12.97%GANXGain Therapeutics11.97%RZLTRezolute82.97%VBLTVascular Biogenics0.96%Insider OwnershipCompanyInsider OwnershipALRNAileron Therapeutics5.57%CLSNImunon4.66%GANXGain Therapeutics11.00%RZLTRezolute18.20%VBLTVascular Biogenics6.13%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALRNAileron Therapeutics616.97 million16.03 millionNot OptionableCLSNImunon277.10 million6.77 millionOptionableGANXGain Therapeutics2816.22 million14.44 millionOptionableRZLTRezolute5740.13 million32.83 millionNot OptionableVBLTVascular Biogenics777.64 million72.88 millionOptionableALRN, GANX, VBLT, RZLT, and CLSN HeadlinesSourceHeadlineTommy Garten elected to VBL Hall of Fametherecorderonline.com - March 28 at 1:31 PMControl of vascular morphogenesis and homeostasis through the angiopoietin–Tie systemnature.com - February 21 at 3:29 PMVascular News and Researchnews-medical.net - November 25 at 2:28 PMVascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26msn.com - November 3 at 12:39 AMNotable Labs Closes Merger Transaction With VBL Therapeuticsfinance.yahoo.com - October 16 at 3:55 PMVBL Therapeutics Announces Results of Annual and Special Shareholder Meetingfinance.yahoo.com - October 12 at 3:13 PMVBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meetingfinance.yahoo.com - October 4 at 8:40 AMVascular Biogenics Rises on Presentation Hypefinance.yahoo.com - September 9 at 12:00 PMVBLT Stock Sees Decline of Approximately -0.22% in Last Five Daysknoxdaily.com - September 7 at 9:15 PMVBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SECfinance.yahoo.com - September 6 at 7:30 PMVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTbusinesswire.com - August 28 at 7:00 PMVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTbusinesswire.com - August 28 at 3:04 PMVBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - August 14 at 8:09 AMMonitoring Vascular Biogenics Ltd. (VBLT) after recent insider movementsknoxdaily.com - July 26 at 4:10 PMVascular Biogenics (NASDAQ: VBLT)fool.com - July 23 at 5:52 PMRecent Insider Activity Suggests Potential Gains for Vascular Biogenics Ltd. (VBLT)knoxdaily.com - July 12 at 4:20 PMVBLT Stock Sees Decline of Approximately -4.31% in Last Five Daysknoxdaily.com - July 7 at 2:11 PMDays-to-cover ratio for VBLT surges to 0.84 due to rise in short interestknoxdaily.com - June 23 at 8:26 PMThe Role of Peripheral Arterial Disease in the Pathogenesis of Diabetic Foot Disease: When to Refer for Vascular Surgerymedscape.com - May 18 at 1:35 AMVBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - May 15 at 8:03 PMDeveloping a Patient-Centered Approach to Vascular Access Device Selectionmedscape.com - May 10 at 8:52 AMCADASIL: The Most Common Hereditary Subcortical Vascular Dementiamedscape.com - May 5 at 1:05 AMAspirin in Stroke Prevention in Nonvalvular Atrial Fibrillation and Stable Vascular Diseasemedscape.com - May 2 at 8:00 PMVascular Biogenics Stock (NASDAQ:VBLT), Dividendsbenzinga.com - April 4 at 1:52 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAileron TherapeuticsNASDAQ:ALRNAileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.ImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Gain TherapeuticsNASDAQ:GANXGain Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies. The company's platform is enhanced with new AI and machine-learning tools and virtual screening capabilities to access the emerging on-demand compound libraries covering chemical spaces of approximately 50 billion compounds. It deploys its platform by accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders, including neurodegenerative diseases, rare genetic disorders, and oncology. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.RezoluteNASDAQ:RZLTRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Vascular BiogenicsNASDAQ:VBLTVascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.